Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

  • Revenue in USD (TTM)92.95bn
  • Net income in USD29.04bn
  • Incorporated1942
  • Employees83.00k
  • Location
    Pfizer Inc66 HUDSON BOULEVARD EASTNEW YORK 10001-2192United StatesUSA
  • Phone+1 (212) 733-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PFE:NYQ since
Lucira Health IncDeal completed06 Apr 202306 Apr 2023Deal completed-7.68%22.40m
Seagen IncAnnounced13 Mar 202313 Mar 2023Announced-2.61%43.84bn
Global Blood Therapeutics IncDeal completed08 Aug 202208 Aug 2022Deal completed-22.14%5.07bn
Data delayed at least 15 minutes, as of Jun 02 2023 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Amgen, Inc.26.19bn7.92bn116.52bn25.20k14.8121.7910.234.4514.7214.7248.7010.010.35411.394.841,039,286.0010.7011.1413.1113.8175.0877.9930.2328.792.795.880.920153.531.322.8711.18-4.107.1111.03
Bristol-Myers Squibb Co45.85bn7.31bn137.94bn34.30k19.134.337.903.013.433.4321.4915.150.46474.325.911,336,676.007.432.809.443.4577.8275.4915.996.981.289.520.5426148.90-0.487217.31-9.5410.141.176.72
Pfizer Inc.92.95bn29.04bn216.55bn83.00k7.562.146.292.335.075.0816.2317.890.48993.037.281,119,904.0015.338.7719.1911.0768.1570.3231.2824.351.1126.120.261757.5323.4313.8139.9521.387.864.56
AbbVie Inc56.74bn7.53bn241.48bn50.00k32.2918.1914.934.264.244.2431.937.530.40864.505.111,134,820.005.477.576.989.6870.9671.5813.3818.430.82118.960.823697.863.3015.522.7415.705.6117.11
Merck & Co Inc57.87bn13.03bn285.51bn69.00k21.966.1016.914.935.125.1222.7618.460.53972.715.72838,681.2012.179.4015.4512.6072.7571.3522.5418.841.1918.090.39671.7921.728.1217.6123.6718.373.48
Data as of Jun 02 2023. Currency figures normalised to Pfizer Inc's reporting currency: US Dollar USD

Institutional shareholders

33.50%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2023484.03m8.61%
BlackRock Fund Advisorsas of 31 Mar 2023295.95m5.27%
SSgA Funds Management, Inc.as of 31 Mar 2023281.83m5.02%
Capital Research & Management Co. (World Investors)as of 31 Mar 2023231.51m4.12%
Wellington Management Co. LLPas of 31 Mar 2023218.93m3.90%
Geode Capital Management LLCas of 31 Mar 2023109.85m1.96%
Charles Schwab Investment Management, Inc.as of 31 Mar 202383.90m1.49%
Norges Bank Investment Managementas of 31 Dec 202261.48m1.09%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202359.01m1.05%
Capital Research & Management Co. (International Investors)as of 31 Mar 202356.00m1.00%
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.